Second DPP-4 inhibitor gets FDA Approval

2nd DPP-4 inhibitor gets FDA Approval
Onglyza™ (saxagliptin) a new DPP-4 inhibitor similar to Januvia will give physicians another option in treating their patients with diabetes. See This Week’s Item #1.